View All Documents & Correspondence
Composition Comprising Sesamol, And Epigallocatechin Gallate And Uses Thereof
Abstract: The present disclosure relates to a composition comprising sesamol and epigallocatechin gallate, the combination of which, at particular w/w ratios allows for enhancement of the ability of cells to take up extracellular glucose. These findings are potentially useful in formulating recipes which seek to control blood sugar levels in people with compromised blood sugar absorption mechanisms.
Notices, Deadlines & Correspondence
Patent Information
Applicants
ITC LIMITED
Inventors
1. DEVAN, Sabarinathan
2. RADHAKRISHNAN, Yashwanth
3. KS, Nandakumar
4. CHANDRASEKHARAN, Lakshmanan Chittur
Specification
Claims:1. An anti-diabetic composition comprising:
a. epigallocatechin gallate; and
b. sesamol,
wherein epigallocatechin gallate to sesamol w/w ratio in said composition is in the range of 1:0.25-1:1.
2. The anti-diabetic composition as claimed in claim 1, wherein epigallocatechin gallate to sesamol w/w ratio in said composition is in the range of 1:0.3-1:0.45.
3. The anti-diabetic composition as claimed in claim 2, wherein epigallocatechin gallate to sesamol w/w ratio in said composition is 1:0.45.
4. The anti-diabetic composition as claimed in claim 2, wherein epigallocatechin gallate to sesamol w/w ratio in said composition is 1:0.3.
5. The anti-diabetic composition as claimed in any of the claims 1-4, further comprising suitable additives.
6. A method of preparing an anti-diabetic composition as claimed in any of the claims 1-4, said method comprising:
a. obtaining sesamol;
b. obtaining epigallocatechin gallate; and
c. contacting sesamol, and epigallocatechin gallate to obtain a composition.
7. A method of preparing an anti-diabetic composition as claimed in claim 5, said method comprising:
a. obtaining sesamol;
b. obtaining epigallocatechin gallate;
c. obtaining suitable additives; and
d. contacting sesamol, epigallocatechin gallate, and suitable additives to obtain a composition.
8. The method as claimed in any of the claims 6-7, wherein epigallocatechin gallate to sesamol w/w ratio in said composition is in the range of 1:0.25-1:1.
9. The method as claimed in claim 8, wherein epigallocatechin gallate to sesamol w/w ratio in said composition is in the range of 1:0.3-1:0.45.
10. The method as claimed in claim 9, wherein epigallocatechin gallate to sesamol w/w ratio in said composition is 1:0.45.
11. The method as claimed in claim 9, wherein epigallocatechin gallate to sesamol w/w ratio in said composition is 1:0.3.
12. A method of blood glucose level management, said method comprising:
a. obtaining an anti-diabetic composition as claimed in any of the claims 1-5; and
b. contacting said composition with blood, wherein said method promotes cellular uptake of glucose.
Dated this October, 2016
, Description:As Attached
Documents
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | Correspondence by Agent_Form26_19-12-2016.pdf | 2016-12-19 |
| 1 | Form5_As Filed_08-11-2016.pdf | 2016-11-08 |
| 2 | Form3_As Filed_08-11-2016.pdf | 2016-11-08 |
| 2 | Correspondence by Agent_Form1_13-12-2016.pdf | 2016-12-13 |
| 3 | Form2 Title Page_Complete_08-11-2016.pdf | 2016-11-08 |
| 3 | Correspondence by Agent_Form26_13-12-2016.pdf | 2016-12-13 |
| 4 | Form26_Power of Attorney_13-12-2016.pdf | 2016-12-13 |
| 4 | Form1_As Filed_08-11-2016.pdf | 2016-11-08 |
| 5 | Abstract_As Filed_08-11-2016.pdf | 2016-11-08 |
| 5 | Drawings_As Filed_08-11-2016.pdf | 2016-11-08 |
| 6 | Claims_As Filed_08-11-2016.pdf | 2016-11-08 |
| 6 | Description Complete_As Filed_08-11-2016.pdf | 2016-11-08 |
| 7 | Claims_As Filed_08-11-2016.pdf | 2016-11-08 |
| 7 | Description Complete_As Filed_08-11-2016.pdf | 2016-11-08 |
| 8 | Abstract_As Filed_08-11-2016.pdf | 2016-11-08 |
| 8 | Drawings_As Filed_08-11-2016.pdf | 2016-11-08 |
| 9 | Form1_As Filed_08-11-2016.pdf | 2016-11-08 |
| 9 | Form26_Power of Attorney_13-12-2016.pdf | 2016-12-13 |
| 10 | Form2 Title Page_Complete_08-11-2016.pdf | 2016-11-08 |
| 10 | Correspondence by Agent_Form26_13-12-2016.pdf | 2016-12-13 |
| 11 | Form3_As Filed_08-11-2016.pdf | 2016-11-08 |
| 11 | Correspondence by Agent_Form1_13-12-2016.pdf | 2016-12-13 |
| 12 | Form5_As Filed_08-11-2016.pdf | 2016-11-08 |
| 12 | Correspondence by Agent_Form26_19-12-2016.pdf | 2016-12-19 |